ClinicalTrials.gg
CompletedNCT03209973Updated Feb 5, 2025Results posted

A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma

A Phase 2 interventional study of Tislelizumab in Classical Hodgkin Lymphoma, sponsored by BeiGene. Completed at 12 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-05.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 57 studies in Hodgkin Disease with a site in China — 28 open to participants now, 31 under way, 3 of them phase 3. Hodgkin Disease · China.

Enrollment
30th of 53
70 · median 75
Started
2017
with 6 others
Phase 2
26 of 57
13 open now
Registered
9th of 57
by date
Lead sponsor
2 of 57
BeiGene

Among the 57 studies in Hodgkin Disease with a site in China, this one is the 30th largest by enrollment of the 53 interventional ones that give a count, is one of 7 that started in 2017, is one of 26 in phase 2, and was the 9th registered.

Hodgkin Disease

1,384 studies on the registry are indexed under Hodgkin Disease; 161 are open to participants now.

Browse Hodgkin Disease studies →

Open to participants now

28 of the 57 studies in Hodgkin Disease with a site in China are open now. Recruiting first, the newest first:

23 more — sign in →

All 28 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 134 Hodgkin Disease studies recruiting now, 71 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Hodgkin Disease with a site in China, or all of them as a file.
02

Study summary

The primary objective of this study was to evaluate the efficacy of tislelizumab assessed by Independent Review Committee (IRC) in participants with relapsed or refractory classical Hodgkin lymphoma (cHL), as measured by Overall Response Rate (ORR) per the Lugano Classification

Read the detailed description

This was an open-label, single-arm, multi-center Phase 2 study. Response was to be assessed by PET(positron emission tomography) and computed tomography (CT) scan per the Lugano Classification. CT scan with contrast and Positron emission tomography (PET)/CT was used as required by protocol, until progressive disease (PD), new anti-cancer therapy, withdrawal of consent, death, lost to follow-up, or end of study (EOS), whichever occurred first. Total body magnetic resonance imaging (MRI) was allowed if CT with contrast is contraindicated. During treatment with immune checkpoint inhibitor such as with tislelizumab, pseudo-progression may occur due to immune cell infiltration and other mechanisms as manifested by apparent increase of existing tumor masses or appearance of new tumor lesions. Participants were allowed to continue study treatment if there is suspicion of pseudo-progression, provided they are asymptomatic and have radiographic progression only, until a second consecutive CT scan demonstrates PD at which time study treatment was discontinued permanently. Participants were evaluated for Adverse Events (AEs) (all Grades per National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.03 [NCI CTCAE v. 4.03]), serious AEs (SAEs), and any AEs requiring study drug interruption or discontinuation.

03

Conditions studied

  • Classical Hodgkin Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. confirmed cHL ( from diagnosis or at any relapse is acceptable).
  2. Participants must have relapsed (disease progression after most recent therapy) or refractory (failure to achieve complete Response (CR) /complete metabolic response [CMR] or partial response (PR) to most recent therapy) cHL and and failed to achieve a response or progressed after auto-SCT or meet the criteria of ineligible for auto-SCT.
  3. Participants must have defined as ≥ 1 nodal lesion that is > 1.5 cm in the longest diameter, or ≥ 1 extra-nodal lesion (e.g. hepatic nodules) that is > 1 cm in the longest diameter.
  4. (ECOG) performance status of 0 or 1.
  5. ≥ 12 weeks.
  6. participants must have adequate organ functions as indicated by the following laboratory values:

    1. (ANC) ≥ 1.5 x 109/L, independent of growth factor support within 7 days of first dose.
    2. ≥ 75 x 109/L, independent of growth factor support or transfusion within 7 days of first dose.
    3. (Hgb) ≥ 8 g/dL or ≥ 5 mmol/L.
    4. Serum creatinine ≤ 1.5 x (ULN).
    5. (AST)/glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT)/glutamic-pyruvic transaminase (SGPT) ≤ 2.5 x upper limit of normal (ULN), or ≤ 5X ULN if liver are present.
    6. Serum total ≤ 1.5 x ULN (total bilirubin level \< 4 x ULN for participants with Gilbert's syndrome).
  7. (INR) ≤ 1.5 x ULN and activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN unless participant is receiving anticoagulant therapy and coagulation parameters (prothrombin time [PT/INR] and aPTT) are within intended therapeutic range of intended use of the anticoagulant at time of Screening. Participants with factor inhibitors prolonging PT or INR may be included after discussion with the medical monitor.
  8. Participants must have no evidence of dyspnea at rest and a pulse oximetry of > 92% while breathing room air.
  9. Participants must have (FEV1)/forced vital capacity (FVC) > 60% by pulmonary function test (PFT); carbon monoxide diffusion capacity (DLCO), FEV1 and FVC all > 50 % predicted value; all PFTs must be obtained within 4 weeks prior to the first dose of tislelizumab.
  10. Prior chemotherapy, radiotherapy, immunotherapy or therapy (including Chinese herbal medicine and Chinese patent medicine) used to control cancer including locoregional treatment must have been completed ≥ 4 weeks before the first dose of tislelizumab, and all treatment-related adverse events are stable and have either returned to baseline or Grade 0/1 (except for alopecia and hemoglobin. For hemoglobin, please follow inclusion criteria #8c [hemoglobin]).

Key Exclusion Criteria:

  1. Nodular lymphocyte-predominant Hodgkin lymphoma or gray zone lymphoma.
  2. Prior hematopoietic stem cell transplant.
  3. History of severe reaction to monoclonal antibodies.
  4. (NYHA) class III or IV heart failure, unstable angina, severe uncontrolled ventricular arrhythmia, electrocardiographic evidence of acute ischemia, or myocardial infarction within 6 months of first day of Screening.
  5. Prior within the past 3 years except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast.
  6. Prior therapy targeting or PD-L1.
  7. Participants with active disease or history of autoimmune disease with high risk of recurrence including but not limited to history of immune-related neurologic disease, multiple sclerosis, autoimmune (demyelinating) neuropathy, Guillain-Barrè syndrome, myasthenia gravis, systemic lupus erythematosus (SLE), connective tissue disease, scleroderma, inflammatory bowel disease including Crohn's disease and ulcerative colitis, autoimmune hepatitis, toxic epidermal necrolysis (TEN), or Stevens-Johnson syndrome.

    Note: Participants is permitted to enroll if he/she has vitiligo, eczema, type I diabetes mellitus, endocrine deficiencies including thyroiditis managed with replacement hormone and/or physiologic . Participants with rheumatoid arthritis and/or other arthropathies, Sjögren's syndrome or psoriasis controlled with topical medication, and participants with positive serology such as positive antinuclear antibody (ANA) or anti-thyroid antibody should be evaluated for presence of target organ involvement and potential need for systemic treatment but should otherwise be eligible.

  8. Conditions requiring systemic treatment with either corticosteroids (> 10 mg daily Prednisone equivalent) or other medications within 14 days of first dose of tislelizumab.

    Note: Adrenal replacement doses of ≤ 10 mg daily Prednisone are permitted in the absence of active autoimmune disease. Topical, ocular, intra-articular, intra-nasal and inhalational corticosteroid (with minimal systemic absorption), a brief course of corticosteroid for prophylaxis (e.g. contrast dye allergy) or for treatment of non-autoimmune conditions (e.g. delayed-type hypersensitivity reaction caused by contact allergen) are allowed.

  9. Has history of interstitial lung disease or non-infectious pneumonitis or has evidence of interstitial lung disease or non infectious pneumonitis currently.
  10. Corrected by the Fridericia Correction Formula (QTcF)interval > 480 msec, unless secondary to bundle branch block.
  11. Serious acute or chronic infection requiring systemic therapy.
  12. Known central nervous system (CNS) lymphoma.
  13. Underlying medical conditions that, in the Investigator's opinion, will render the administration of study drug hazardous or obscure the interpretation of toxicity or adverse events.
  14. Autologous hematopoietic stem cell transplant within 100 days of first dose of tislelizumab.
  15. Use of any against infectious diseases (e.g. influenza, varicella, etc.) within 4 weeks (28 days) of the first dose of tislelizumab, and any intended use within 60 days after the last dose of tislelizumab.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Tislelizumab

    Tislelizumab 200 mg administered intravenously (IV) every-3-weeks (Q3W)

    Drug: Tislelizumab

Interventions

  • Administered as specified in the treatment arm

    Also known as: BGB-A317

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as the proportion of participants who achieve a best response of Complete Response (CR) or Partial Response (PR), as assessed by Independent Review committee (IRC) per the Lugano Classification

    Time frame: From the date of first dose Up to approximately 3 year and 7 months

Secondary outcomes

  1. Progression-free Survival (PFS)

    PFS is defined as the time from the first dose of tislelizumab to the date of Progressive Disease (PD) or death, whichever occurs first, assessed by IRC per the Lugano Classification

    Time frame: From the date of first dose until end of study (Up to approximately 3 years and 7 months)

  2. Duration of Response (DOR)

    DOR is defined as the time from the date that response criteria are first met to the date that PD is objectively documented or death, whichever occurs first, assessed by IRC per the Lugano Classification

    Time frame: From the date of first dose until end of study (Up to approximately 3 years and 7 months)

  3. Rate of Complete Response (CRR)

    CRR is defined as the percentage of participants who achieve a best response of CR, assessed by IRC per the Lugano Classification

    Time frame: From the date of first dose until end of study (Up to approximately 3 years and 7 months)

  4. Time to Response (TTR)

    TTR is defined as the time from the date of the first dose of tislelizumab to the time the response criteria are first met, assessed by IRC per the Lugano Classification

    Time frame: From the date of first dose until end of study (Up to approximately 3 years and 7 months)

  5. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. An SAE is any untoward medical occurrence that, at any dose: * Results in death. * Is life-threatening. * Requires hospitalization or prolongation of existing hospitalization * Results in disability/incapacity * Is a congenital anomaly/birth defect * Is considered a significant medical AE by the investigator based on medical judgement

    Time frame: From the date of first dose until end of study (Up to approximately 3 years and 7 months)

  6. Number of Participants With Significant Changes in Clinical Laboratory Results

    Clinical laboratory (e.g. hematology, serum chemistry, urinalysis) values were evaluated for each laboratory parameter and participants with clinically significant changes are summarized.

    Time frame: From the date of first dose until end of study (Up to approximately 3 years and 7 months)

  7. Number of Participants With Significant Changes in Electrocardiograms

    Time frame: From the date of first dose until end of study (Up to approximately 3 years and 7 months)

07

Results

Posted Oct 12, 2020

Participant flow

70 participants were enrolled at 11 sites in China. The first participant dose date was on 21 April 2017. The study was completed on 02 November 2020.

Participant flow — Overall Study
MilestoneTislelizumab
Started70
Completed primary outcome period66
Completed0
Not completed70
Withdrew: Withdrawal by subject7
Withdrew: Lost to follow-up2
Withdrew: Death8
Withdrew: Transferred to long term extension (lte) study32
Withdrew: Sponsor decision18
Withdrew: Participant withdrew due to higher risk than benefit of treatment1
Withdrew: Participant refused to return to treatment2

Outcome measures

PrimaryOverall Response Rate (ORR)

ORR is defined as the proportion of participants who achieve a best response of Complete Response (CR) or Partial Response (PR), as assessed by Independent Review committee (IRC) per the Lugano Classification

Time frame:
From the date of first dose Up to approximately 3 year and 7 months
Reported as:
Number · Percentage of Participants
Overall Response Rate (ORR)
Percentage of ParticipantsTislelizumab
Overall Response Rate (ORR)87.1 (77.0 to 93.9)
Statistical analysis
  • Tislelizumab · Exact Binomial Test · p = <0.0001 (1-sided p-value was based on exact test of BGB-A317 versus historical rate of 0.35)Comparison with historical control values
SecondaryProgression-free Survival (PFS)

PFS is defined as the time from the first dose of tislelizumab to the date of Progressive Disease (PD) or death, whichever occurs first, assessed by IRC per the Lugano Classification

Time frame:
From the date of first dose until end of study (Up to approximately 3 years and 7 months)
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsTislelizumab
Progression-free Survival (PFS)31.5 (16.53 to NA)
SecondaryDuration of Response (DOR)

DOR is defined as the time from the date that response criteria are first met to the date that PD is objectively documented or death, whichever occurs first, assessed by IRC per the Lugano Classification

Time frame:
From the date of first dose until end of study (Up to approximately 3 years and 7 months)
Reported as:
Median · Months
Duration of Response (DOR)
MonthsTislelizumab
Duration of Response (DOR)31.3 (20.73 to NA)
SecondaryRate of Complete Response (CRR)

CRR is defined as the percentage of participants who achieve a best response of CR, assessed by IRC per the Lugano Classification

Time frame:
From the date of first dose until end of study (Up to approximately 3 years and 7 months)
Reported as:
Median · Percentage of participants
Rate of Complete Response (CRR)
Percentage of participantsTislelizumab
Rate of Complete Response (CRR)67.1 (54.9 to 77.9)
SecondaryTime to Response (TTR)

TTR is defined as the time from the date of the first dose of tislelizumab to the time the response criteria are first met, assessed by IRC per the Lugano Classification

Time frame:
From the date of first dose until end of study (Up to approximately 3 years and 7 months)
Reported as:
Median · Weeks
Time to Response (TTR)
WeeksTislelizumab
Time to Response (TTR)12.0 (11.86 to 12.29)
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

An adverse event (AE) is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. An SAE is any untoward medical occurrence that, at any dose: * Results in death. * Is life-threatening. * Requires hospitalization or prolongation of existing hospitalization * Results in disability/incapacity * Is a congenital anomaly/birth defect * Is considered a significant medical AE by the investigator based on medical judgement

Time frame:
From the date of first dose until end of study (Up to approximately 3 years and 7 months)
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsTislelizumab
Participants with At least one TEAE68
SAE18
SecondaryNumber of Participants With Significant Changes in Clinical Laboratory Results

Clinical laboratory (e.g. hematology, serum chemistry, urinalysis) values were evaluated for each laboratory parameter and participants with clinically significant changes are summarized.

Time frame:
From the date of first dose until end of study (Up to approximately 3 years and 7 months)
Reported as:
Number · Participants
Number of Participants With Significant Changes in Clinical Laboratory Results
ParticipantsTislelizumab
Number of Participants With Significant Changes in Clinical Laboratory Results0
SecondaryNumber of Participants With Significant Changes in Electrocardiograms
Time frame:
From the date of first dose until end of study (Up to approximately 3 years and 7 months)
Reported as:
Number · Participants
Number of Participants With Significant Changes in Electrocardiograms
ParticipantsTislelizumab
Postbaseline corrected QT interval > 450 msec0
≥ 1 postbaseline electrocardiogram21
Increase corrected QT interval of ≤ 30 msec18
Increase > 30 msec but ≤ 60 msec corrected QT interval4

Adverse events

Collected over From the date of first dose until end of study (Up to approximately 3 years and 7 months). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tislelizumab8/70 (11.4%)18/70 (25.7%)68/70 (97.1%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventTislelizumab
PyrexiaGeneral disorders2/70
PneumoniaInfections and infestations2/70
PneumonitisRespiratory, thoracic and mediastinal disorders2/70
NeutropeniaBlood and lymphatic system disorders1/70
ThrombocytopeniaBlood and lymphatic system disorders1/70
AscitesGastrointestinal disorders1/70
DeathGeneral disorders1/70
Hepatitis BInfections and infestations1/70
Pneumocystis jirovecii pneumoniaInfections and infestations1/70
Upper respiratory tract infectionInfections and infestations1/70
Most frequent other events
Showing 10 of 55
Most frequent other events
EventTislelizumab
PyrexiaGeneral disorders40/70
Upper respiratory tract infectionInfections and infestations27/70
HypothyroidismEndocrine disorders26/70
Weight increasedInvestigations24/70
White blood cell count decreasedInvestigations15/70
CoughRespiratory, thoracic and mediastinal disorders15/70
Alanine aminotransferase increasedInvestigations14/70
PruritusSkin and subcutaneous tissue disorders13/70
Weight decreasedInvestigations12/70
Aspartate aminotransferase increasedInvestigations11/70

Baseline characteristics

Safety Analysis Set: All participants who received any dose of study drug.

Age, Continuous
Age, Continuous(years)Tislelizumab
Mean36.2 ± 12.73
Age, Customized
Age, Customized(Participants)Tislelizumab
<6566
≥ 65 and < 75 years4
≥ 750
Sex: Female, Male
Sex: Female, Male(Participants)Tislelizumab
Female30
Male40
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Tislelizumab
Chinese70
Region of Enrollment
Region of Enrollment(Participants)Tislelizumab
China70
08

Study locations

12 sites
  • Beijing Cancer Hospital
    Beijing, Beijing 100142, China
  • Chinese Pla General Hospital
    Beijing, Beijing 100853, China
  • Fujian Cancer Hospital
    Fuzhou, Fujian 350014, China
  • Henan Cancer Hospital
    Zhengzhou, Henan 450000, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology
    Wuhan, Hubei 430030, China
  • Jiangsu Province Hospital
    Nanjing, Jiangsu 210029, China
  • The First Hospital of Jilin University
    Changchun, Jilin 130021, China
  • Fudan University Shanghai Cancer Center
    Shanghai, Shanghai 200000, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan 610041, China
  • Institute of Hematology and Hospital of Blood Disease
    Tianjin, Tianjin 300020, China
  • Tianjin Medical University Cancer Institute and Hospital
    Tianjin, Tianjin 300060, China
  • Zhejiang Cancer Hospital
    Hangzhou, Zhejiang 310022, China
09

References and documents

Publications

  • Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, Li W, Yang H, Liu T, Wang Q, Lv F, Guo H, Yang L, Elstrom R, Huang J, Novotny W, Wei V, Zhu J. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. Leukemia. 2020 Feb;34(2):533-542. doi: 10.1038/s41375-019-0545-2. Epub 2019 Sep 13. PubMed 31520078 ↗
  • Song Y, Gao Q, Zhang H, Fan L, Zhou J, Zou D, Li W, Yang H, Liu T, Wang Q, Lv F, Guo H, Zhao X, Wang D, Zhang P, Wang Y, Wang L, Liu T, Zhang Y, Shen Z, Huang J, Zhu J. Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis. Clin Cancer Res. 2022 Mar 15;28(6):1147-1156. doi: 10.1158/1078-0432.CCR-21-2023. PubMed 34716199 ↗
  • Chen J, Zhang H, Zhu L, Zhao Y, Ding Y, Yuan Y. Tislelizumab for the treatment of classical Hodgkin's lymphoma. Drugs Today (Barc). 2020 Dec;56(12):781-785. doi: 10.1358/dot.2020.56.12.3233362. PubMed 33332484 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Nov 2020, 42 months.

Of 203 phase 2 interventional studies under Hodgkin Disease, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 111. This study's 42 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2017
First posted
Jul 6, 2017
StartActual
Apr 21, 2017
Primary completionActual
Nov 2, 2020
CompletionActual
Nov 2, 2020
Results first posted
Oct 12, 2020
Last update
Feb 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03209973
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Jul 6, 2017
Start date
Apr 21, 2017
Primary completion
Nov 2, 2020
Completion
Nov 2, 2020
Results posted
Oct 12, 2020
Last update
Feb 5, 2025

Study contacts

Study Director
principal investigator · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion